Pfizer doc sounds off on drug development

In a discussion with The New York Times, Pfizer research chief Dr. John L. LaMattina discusses the drug giant's ups and downs and the challenges of fostering innovation in the world's largest drug company. Critics note that Pfizer's low product output could be due to increased bureaucracy and less autonomy among its researchers. But LaMattina reminds readers that in this business, success is measured in decades and that Pfizer's all-important experimental drug pipeline will deliver promising treatments in the years to come. He's optimistic that Pfizer, along with the drug industry as a whole, is entering a new age in drug development that will revolutionize medicine.

- for more, read this The New York Times article

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.